2022-503037-63-00已完成1 期
A two-part, open-label study to assess the pharmacokinetics, pharmacodynamics and safety of single doses of inhaled and intravenously administered D,L lysine acetylsalicylate • glycine (LASAG) in healthy adult subjects: Study Part A follows a randomized, cross-over design to compare three dose levels of inhaled LASAG to one dose level of intravenously administered LASAG and Study Part B follows a single group design to investigate a XXXXX LASAG inhalation solution.
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 发起方
- Aspiair GmbH
- 入组人数
- 28
- 试验地点
- 1
研究概览
简要总结
暂无简介。
入排标准
- 年龄范围
- 18 years 至 64 years(18-64 Years)
- 接受健康志愿者
- 是
入选标准
- 未提供
排除标准
- 未提供
研究者
Sebastian Canisius
Scientific
Aspiair GmbH
研究点 (1)
Loading locations...
相似试验
已完成
2 期
ilotinib treatment cessation studyChronic Myeloid LeukemiaJPRN-jRCT2080222098ovartis Pharma117
进行中(未招募)
1 期
A clinical research study evaluating the possibility to stop the drug nilotinib (Tasigna) in chronic myeloid leukemia (CML) patients who have very small amount of leukemia cells remaining after nilotinib (Tasigna) treatment.EUCTR2012-003186-18-GBovartis Pharma Services AG163
进行中(未招募)
不适用
A clinical research study evaluating the possibility to stop the drug nilotinib (Tasigna) in chronic myeloid leukemia (CML) patients who have very small amount of leukemia cells remaining after nilotinib (Tasigna) treatment.EUCTR2012-003186-18-ESovartis Farmacéutica S.A.117
进行中(未招募)
1 期
A clinical research study evaluating the possibility to stop the drug nilotinib (Tasigna) in chronic myeloid leukemia (CML) patients who have very small amount of leukemia cells remaining after nilotinib (Tasigna) treatment.Ph+ chronic myeloid leukemia (CML)MedDRA version: 19.0Level: LLTClassification code 10054352Term: Chronic phase chronic myeloid leukemiaSystem Organ Class: 100000004864EUCTR2012-003186-18-BEovartis Pharma Services AG117
进行中(未招募)
1 期
A clinical research study evaluating the possibility to stop the drug nilotinib (Tasigna) in chronic myeloid leukemia (CML) patients who have very small amount of leukemia cells remaining after nilotinib (Tasigna) treatment.Ph+ chronic myeloid leukemia (CML)MedDRA version: 14.1Level: LLTClassification code 10054352Term: Chronic phase chronic myeloid leukemiaSystem Organ Class: 100000004864EUCTR2012-003186-18-GRovartis Pharma Services AG117
